Medicxi Ventures Management (Jersey) Ltd Long-Term Concentrated

Name: Medicxi Ventures Management (Jersey) Ltd Q2 2023 13F Filing | 13F Explorer
Creator: Medicxi Ventures Management (Jersey) Ltd
Published: 2023-07-19

Location: St. Helier, Jersey

CIK: 0001715579 · Show all filings

Period: Q2 2023 (← Previous) (Next →)

Filing Date: Jul 19, 2023

Total Value: $357M (100.0% shares, 0.0% debt)

Holdings (6)

CNTA CENTESSA PHARMACEUTICALS PLC 34.6%

Value $124M Shares 19,963,157 Est. Cost $20.88 Unrealized —

PCVX VAXCYTE INC 18.4%

Value $65.69M Shares 1,315,435 Est. Cost $32.16 Unrealized +47.4%

PHAT PHATHOM PHARMACEUTICALS INC 15.1%

Value $53.86M Shares 3,760,869 Est. Cost $18.86 Unrealized -38.9%

— MERUS N V 11.8%

Value $42.13M Shares 1,600,000 Est. Cost $14.08 Unrealized —

AURA AURA BIOSCIENCES INC 10.5%

Value $37.54M Shares 3,039,892 Est. Cost $17.87 Unrealized -40.2%

NAMS NEWAMSTERDAM PHARMA COMPANY 9.6%

Value $34.12M Shares 2,869,565 Est. Cost $10.96 Unrealized +21.1%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CNTA	CENTESSA PHARMACEUTICALS PLC	19,963,157	$124M	34.6%	$20.88	—	SPONSORED ADS	152309100
PCVX	VAXCYTE INC	1,315,435	$65.69M	18.4%	$32.16	+47.4%	COM	92243G108
PHAT	PHATHOM PHARMACEUTICALS INC	3,760,869	$53.86M	15.1%	$18.86	-38.9%	COM	71722W107
—	MERUS N V	1,600,000	$42.13M	11.8%	$14.08	—	COM	N5749R100
AURA	AURA BIOSCIENCES INC	3,039,892	$37.54M	10.5%	$17.87	-40.2%	COM	05153U107
NAMS	NEWAMSTERDAM PHARMA COMPANY	2,869,565	$34.12M	9.6%	$10.96	+21.1%	ORDINARY SHARES	N62509109